SVP of Finance CFO of Intra-cellular Therapies Inc (30-Year Financial, Insider Trades) Lawrence J. Hineline (insider trades) sold 28,034 shares of ITCI on 11/11/2020 at an average price of $25.41 a share. The total sale was $712,344.
Intra-Cellular Therapies Inc is a biopharmaceutical company. It is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders. Intra-Cellular Therapies Inc has a market cap of $2.15 billion; its shares were traded at around $26.77 with and P/S ratio of 174.97. GuruFocus has detected 4 severe warning signs with Intra-Cellular Therapies Inc. .
CEO Recent Trades:
- Chairman, President & CEO Sharon Mates sold 50,000 shares of ITCI stock on 11/10/2020 at the average price of $26.34. The price of the stock has increased by 1.63% since.
- Chairman, President & CEO Sharon Mates sold 50,000 shares of ITCI stock on 11/04/2020 at the average price of $25. The price of the stock has increased by 7.08% since.
CFO Recent Trades:
- SVP of Finance CFO Lawrence J. Hineline sold 28,034 shares of ITCI stock on 11/11/2020 at the average price of $25.41. The price of the stock has increased by 5.35% since.
Directors and Officers Recent Trades:
- EVP, Chief Commercial Officer Mark Neumann sold 6,792 shares of ITCI stock on 10/16/2020 at the average price of $26.8. The price of the stock has decreased by 0.11% since.
For the complete insider trading history of ITCI, click here
.
